The number people want is $299, and it is real, and it is the price of the first month. Zepbound is priced by dose, the dose climbs by design, and the doses that do the work are more than twice that. This page prices the whole ladder, because a monthly figure that ignores the ladder is not a cost, it is a teaser.
Lilly's self-pay prices, every dose
Since 2024 Lilly has sold Zepbound directly to people paying cash, first as a vial and now also as a multi-dose KwikPen, at prices it publishes:1
| Dose | Per month, self-pay | Role in the ladder |
|---|---|---|
| 2.5 mg | $299 | starting dose only, four weeks |
| 5 mg | $399 | first maintenance dose |
| 7.5 mg | $499 | |
| 10 mg | $699 | the trial doses start here |
| 12.5 mg | $699 | |
| 15 mg | $699 | maximum |
A month is 28 days, four weekly doses. The vial comes as a four-count carton of single-dose vials; the KwikPen holds four doses in one pen.3 Both cost the same at the same strength.
Why $299 is not your monthly cost
Lilly says it plainly on its own site: "2.5 mg is the starting dose and is not an approved maintenance dose."4 The label puts you on 2.5 mg for four weeks, then 5 mg, then upward in 2.5 mg steps every four weeks as tolerated, to whichever dose you settle at.3 Most people do not settle at 5 mg. The head-to-head trial that produced Zepbound's 20.2% result ran everyone up to 10 or 15 mg.5 Those are the $699 rungs.
So the honest cost of Zepbound without insurance is a year, not a month:
| Scenario | Year one | Each year after |
|---|---|---|
| Climb to 5 mg and hold | $299 + 11 × $399 = $4,688 | $4,788 |
| Climb to 7.5 mg and hold | $299 + $399 + 10 × $499 = $5,688 | $5,988 |
| Climb to 10 mg and hold | $299 + $399 + $499 + 9 × $699 = $7,488 | $8,388 |
| Climb to 15 mg and hold | $299 + $399 + $499 + $699 + $699 + 7 × $699 = $7,488 | $8,388 |
Read the last two rows together. Once you pass 7.5 mg the price stops climbing, so 10, 12.5 and 15 mg cost the same. The expensive decision is whether you go above 7.5 mg at all, and the trial evidence says that is where the results are. Budget for $699, and treat anything less as a bonus.
The Zepbound page keeps the ladder and its prices current, and the Wegovy dosing chart shows the alternative shape, where Novo's pen price stays flat as the dose rises.
Vial or KwikPen
The self-pay programme started with vials only, and "Zepbound vial" is still what many people search for. The difference is now purely mechanical: the vial needs a separate syringe and you draw the dose yourself; the KwikPen is a multi-dose pen with four fixed doses, dialled and injected like the single-dose pens that go through insurance. Same drug, same strengths, same price. Lilly lists both under self-pay at every dose.1
The single-dose pen, the one most people picture, is the insurance product. It is the form the $25 savings card applies to, and it is not sold at the self-pay prices above.
The savings card does not apply to you
This is the mistake that costs uninsured people a wasted phone call. The Zepbound Savings Card, the "as low as $25" one, requires "commercial drug insurance with coverage for Zepbound", and it excludes government beneficiaries.2 No insurance means no card. The self-pay prices above are the entirety of what Lilly offers a cash patient, and there is no coupon that sits on top of them.
The one route Lilly does offer the uninsured beyond self-pay is patient assistance through the Lilly Cares Foundation, which is income-tested and excludes people on Medicaid or VA benefits. It is slow and it requires your prescriber, and it is worth asking about before committing to $8,000 a year. The general uninsured guide covers how that works.
The cheaper route: compounded tirzepatide
Zepbound's molecule, tirzepatide, is also sold compounded by licensed pharmacies through telehealth programs. It is the same active ingredient at a fraction of the price, and it is not FDA-approved: the finished product has not been reviewed for safety, effectiveness or manufacturing quality, and the pharmacy's own licensing carries that weight. That trade is real and it is yours to make. Here is what it costs today, from every seller we track, each price read from the seller's own page:
From $119 a month against Lilly's $299 starting tier and $699 maintenance tier. Over a year at maintenance that is roughly $1,400 against $8,400. Before choosing that route, check the seller in ten minutes; the price gap is large enough to attract bad actors as well as good pharmacies.
Cash versus a plan that covers it
If you have commercial insurance, the first thing to find out is whether it covers Zepbound at all, because that changes the answer from $699 to $25. It is plan-specific, and it is often refused. The coverage sheets quote eight insurers' own documents on Zepbound; the pattern is that most say it depends on the plan and require prior authorisation, TRICARE covers it, and Humana does not. If yours refuses, the appeal guide is the next step, and self-pay is the fallback while you wait.
Where that leaves you
- Uninsured, want the branded product: Lilly self-pay, $299 the first month, then $399, $499, and $699 from 10 mg. Plan on $699.
- Uninsured, want tirzepatide at a price you can sustain: compounded, from $119 a month on the board above, with the FDA-approval trade-off stated plainly.
- Uninsured and low-income: ask your prescriber about Lilly Cares before paying cash.
- Insured but denied: appeal, and use self-pay or compounded as the bridge, not the retail list price.
The honest summary
Zepbound without insurance is $299 for one month and about $8,400 a year at the doses that produce the results it is famous for. Lilly's programme is a genuine improvement on a list price of up to $1,086 per fill, and it is the only branded route for the uninsured, because the $25 card is not for you. The alternative is the same molecule, compounded, from $119 a month, with the loss of FDA review as the price of the discount.